AstraZeneca puts €307m in Irish Alexion plant
Following the $39bn Alexion buy-out completed in July, AstraZeneca plc announced it will invest €307m in the company’s producion site near Dublin.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1997 entries already.
Entries by Thomas Gabrielczyk
Touchlight extends funding round to boost DNA vector manufacture
UK-based DNA synthesis specialist Touchlight Ltd has extended a funding round to a current aggregate total of US $125m.
What are the Ingredients of an mRNA Vaccine?
mRNA technology has revolutionized vaccine development. What are the chemical components that make up a typical mRNA vaccine and what are their functions? What analytical testing can be done to support this?
Do you really know what is in your vaccine?
CAD is a universal detector able to detect all non-volatile, and many semi-volatile analytes. This uniform response enables accurate quantitation of most excipients in a vaccine formulation.
Facelift for reusable pipette tip boxes
The new box is now called Box 2.0. The new design is a consistent, modern further development of the original product outfit.
Swiss Biotech Day shows great biopharma ambitions
The Swiss biopharmaceutical industry is on the verge of record growth: This was demonstrated at the live Swiss Biotech Day in Basel.
EuropaBio lobbies for better Orphan Drug rules
EuropaBio has responded to the European Commissions public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.
Call for pull incentives to get started
With new backing from large pharma, rising investors interest, and new incubators on stage, the AMR community is now urging policy makers worldwide to bring pull incentives into reality.
Cardior bags €64m in Series B Financing
Cardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure.
ERS Genomics and Cellular Engineering Technologies collaborating
ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.